GlassScriptPhysician profile
John A Martucci
NPI 1083111207
$26,508.19
in general payments reported to CMS, 2019-2025
34 companies · $5,188 in 2025
The $5,188 reported for 2025 was more than what 93% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $1,803 · 2021: $3,013 · 2022: $2,822 · 2023: $2,000 · 2024: $10K · 2025: $5,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $2,494 · Travel and Lodging: $1,329 · Education: $68.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,687.50 |
| Food and Beverage | $2,494.27 |
| Travel and Lodging | $1,329.34 |
| Education | $68.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirus, LLC | $13,687.50 | 2024-2025 | Atlas Plating System, Atlas Foot and Ankle Plating System |
| Stryker Corporation | $5,845.32 | 2019-2025 | Prostep, Prostep Mica, Variax |
| Kairos Surgical INC | $1,207.11 | 2020 | |
| Novastep INC. | $1,124.43 | 2022-2023 | Creed Ortholocent Implants |
| Paragon 28, INC. | $986.21 | 2021-2024 | Ttc Nail, Apex 3d |
| Integra Lifesciences Corporation | $920.06 | 2019-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $825.73 | 2019-2025 | Stravix, Grafix, Stravix Pl |
| Lifenet Health | $234.19 | 2024-2025 | Theragenesis Wound Matrix |
| Wright Medical Technology, INC. | $229.53 | 2019-2020 | |
| Melinta Therapeutics, LLC | $211.40 | 2019-2023 | Kimyrsa |
| Abbvie INC. | $139.99 | 2021-2022 | |
| Horizon Therapeutics Plc | $122.55 | 2022 | |
| In2bones USA, LLC | $112.58 | 2022 | |
| Derma Sciences, INC. | $102.71 | 2019 | |
| Depuy Synthes Sales INC. | $97.59 | 2023 | Speed, Na |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $91.82 | 2020-2025 | Puraply, Puraply Wound Matrix |
| Nevro Corp. | $64.60 | 2021-2022 | |
| Medtronic, INC. | $57.76 | 2023-2025 | Intellis Adaptivestim |
| Grt US Holding, INC. | $53.21 | 2022 | |
| Cardiovascular Systems INC. | $48.91 | 2022 | |
| Zimmer Biomet Holdings, INC. | $43.75 | 2021 | |
| Kci USA, INC. | $43.28 | 2021-2023 | Activ.A.C. |
| Arthrex, INC. | $40.00 | 2022 | |
| Orthofix Medical, INC. | $37.37 | 2019 | |
| Ortho Solutions INC | $27.76 | 2023 | |
| Polymedics Innovations INC. | $26.21 | 2023 | |
| Bioventus LLC | $24.71 | 2024 | Exogen Ultrasound Bone Healing System |
| Kowa Pharmaceuticals America, INC. | $20.21 | 2022 | |
| Medline Industries LP | $15.72 | 2020 | |
| Nabriva Therapeutics, Plc | $14.65 | 2022 | |
| Amgen INC. | $14.49 | 2024 | Krystexxa |
| Anika Therapeutics, INC. | $12.77 | 2022 | |
| Baxter Healthcare | $12.54 | 2020 | |
| Misonix INC | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Martucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.